Also known as: Allogene Therapeutics
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T cell therapies for cancer and autoimmune disease. The company is building off-the-shelf cell therapy candidates designed for broader patient access and scalable manufacturing.
The FDA granted RMAT designation to Allogene’s cema-cel for first-line LBCL consolidation and Cellectis’ lasme-cel for r/r B-ALL. Both allogeneic CAR-T therapies showed promising early efficacy and safety, with cema-cel also receiving Fast Track status.
Allogene Therapeutics said it will present interim futility analysis data from the Phase 2 ALPHA3 trial of cema-cel in first-line consolidation LBCL on April 13, 2026. The readout will assess day-45 MRD clearance in 12 patients per arm randomized to cema-cel or observation.
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07085104 |
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease |
RECRUITING | PHASE1 |
| NCT06500273 |
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL |
RECRUITING | PHASE2 |
| NCT04696731 |
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04093596 |
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) |
COMPLETED | PHASE1 |
